Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease.

Biomarkers Granulocyte-Macrophage Colony-Stimulating Factor / genetics Humans Monocytes / metabolism Parkinson Disease / drug therapy Proteomics Recombinant Proteins Treatment Outcome
GM-CSF Parkinson's disease biomarkers monocytes proteomics scRNA-seq

Journal

Clinical and translational medicine
ISSN: 2001-1326
Titre abrégé: Clin Transl Med
Pays: United States
ID NLM: 101597971

Informations de publication

Date de publication:
07 2022
Historique:
revised: 11 06 2022
received: 11 04 2022
accepted: 17 06 2022
entrez: 8 7 2022
pubmed: 9 7 2022
medline: 14 7 2022
Statut: ppublish

Résumé

Dysregulation of innate and adaptive immunity heralds both the development and progression of Parkinson's disease (PD). Deficits in innate immunity in PD are defined by impairments in monocyte activation, function, and pro-inflammatory secretory factors. Each influences disease pathobiology. To define monocyte biomarkers associated with immune transformative therapy for PD, changes in gene and protein expression were evaluated before and during treatment with recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim, Leukine This monocyte profile provides an "early" and unique biomarker strategy to track clinical immune-based interventions, but requiring validation in larger case studies.

Sections du résumé

BACKGROUND
Dysregulation of innate and adaptive immunity heralds both the development and progression of Parkinson's disease (PD). Deficits in innate immunity in PD are defined by impairments in monocyte activation, function, and pro-inflammatory secretory factors. Each influences disease pathobiology.
METHODS AND RESULTS
To define monocyte biomarkers associated with immune transformative therapy for PD, changes in gene and protein expression were evaluated before and during treatment with recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim, Leukine
CONCLUSIONS
This monocyte profile provides an "early" and unique biomarker strategy to track clinical immune-based interventions, but requiring validation in larger case studies.

Identifiants

DOI: 10.1002/ctm2.958 PMID: 35802825 PMC: PMC9270000
pubmed: 35802825
doi: 10.1002/ctm2.958
pmc: PMC9270000
doi:

Substances chimiques

Biomarkers 0
Recombinant Proteins 0
sargramostim 5TAA004E22
Granulocyte-Macrophage Colony-Stimulating Factor 83869-56-1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e958

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS034239
Pays : United States

Informations de copyright

© 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

Références

BMC Bioinformatics. 2021 Jun 2;22(Suppl 6):130
pubmed: 34078287
Cell Mol Neurobiol. 2018 Nov;38(8):1539-1550
pubmed: 30288631
Cold Spring Harb Perspect Med. 2012 May;2(5):a009274
pubmed: 22553499
NPJ Parkinsons Dis. 2021 May 13;7(1):41
pubmed: 33986285
PLoS One. 2021 Feb 12;16(2):e0240707
pubmed: 33577605
PLoS One. 2013;8(1):e55375
pubmed: 23383169
Nat Commun. 2013;4:1562
pubmed: 23463005
Immunol Res. 2014 May;58(2-3):374-7
pubmed: 24781193
Eur J Immunol. 1998 May;28(5):1719-26
pubmed: 9603479
J Neuroinflammation. 2007 Mar 20;4:10
pubmed: 17374157
Eur J Neurosci. 2019 Feb;49(3):364-383
pubmed: 30474172
Mol Neurodegener. 2020 Jun 5;15(1):32
pubmed: 32503641
Neurotherapeutics. 2020 Oct;17(4):1861-1877
pubmed: 32638217
Nature. 1998 Sep 17;395(6699):297-300
pubmed: 9751060
Sci Rep. 2020 Apr 7;10(1):6261
pubmed: 32253373
Eur J Neurol. 2014 Mar;21(3):388-94
pubmed: 23631635
Bioinformatics. 2009 Apr 15;25(8):1091-3
pubmed: 19237447
Alzheimers Dement (N Y). 2021 Mar 24;7(1):e12158
pubmed: 33778150
Nat Rev Immunol. 2013 Nov;13(11):815-29
pubmed: 24319779
Acta Neuropathol. 2016 Mar;131(3):379-91
pubmed: 26576561
Cells. 2019 Oct 25;8(11):
pubmed: 31731485
Comput Biol Chem. 2008 Dec;32(6):462-8
pubmed: 18757239
NPJ Parkinsons Dis. 2017 Mar 23;3:10
pubmed: 28649610
Neurobiol Dis. 2020 Apr;137:104760
pubmed: 31978602
Parkinsonism Relat Disord. 2011 Feb;17(2):77-83
pubmed: 20851033
Front Aging Neurosci. 2021 Jul 08;13:702639
pubmed: 34305577
Neuroimmunomodulation. 2016;23(1):58-66
pubmed: 26886382
Front Immunol. 2019 Sep 20;10:2199
pubmed: 31616414
J Cereb Blood Flow Metab. 2008 Jan;28(1):29-43
pubmed: 17457367
J Biol Chem. 2007 Mar 16;282(11):8036-43
pubmed: 17227760
EBioMedicine. 2021 May;67:103380
pubmed: 34000620
J Immunol. 1997 Dec 15;159(12):6226-33
pubmed: 9550426
Front Cell Dev Biol. 2020 Sep 08;8:573696
pubmed: 33015066
Int J Neurosci. 2015;125(9):645-54
pubmed: 25202803
J Neurochem. 2007 Jan;100(2):503-19
pubmed: 17241161
J Immunol. 1995 Aug 1;155(3):1428-33
pubmed: 7636208
Exp Cell Res. 2015 Apr 10;333(1):21-38
pubmed: 25684710
Front Cell Dev Biol. 2018 Oct 02;6:128
pubmed: 30333975
Exp Neurol. 2018 Feb;300:179-187
pubmed: 29155051
Can J Psychiatry. 2016 Aug;61(8):457-69
pubmed: 27412728
Neurobiol Dis. 2018 Jan;109(Pt B):249-257
pubmed: 28400134
Mol Neurodegener. 2018 May 21;13(1):26
pubmed: 29783988
Arthritis Res Ther. 2016 Dec 1;18(1):287
pubmed: 27908288
Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3374-9
pubmed: 18296641
Ann Neurol. 2019 Oct;86(4):593-606
pubmed: 31343083
J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):795-808
pubmed: 32576618
Neurobiol Dis. 2019 Jul;127:193-209
pubmed: 30818064
J Mol Biol. 2020 Apr 3;432(8):2651-2672
pubmed: 32061929
Neurochem Res. 2014;39(3):576-92
pubmed: 23729298
Trends Biochem Sci. 2015 Apr;40(4):200-10
pubmed: 25757399
Neurosci Bull. 2017 Oct;33(5):585-597
pubmed: 28936761
Retrovirology. 2015 Jan 22;12:5
pubmed: 25608975
Nat Rev Drug Discov. 2016 Dec 29;16(1):53-70
pubmed: 28031576
Mov Disord. 2019 Nov;34(11):1711-1721
pubmed: 31449711
J Clin Invest. 2009 Jan;119(1):182-92
pubmed: 19104149
Immune Netw. 2018 Aug 13;18(4):e27
pubmed: 30181915
J Biol Chem. 2002 Oct 18;277(42):39312-9
pubmed: 12167619
Cell. 2016 Apr 21;165(3):535-50
pubmed: 27104977
Behav Brain Res. 2001 Nov 1;125(1-2):279-84
pubmed: 11682119
Protein Cell. 2015 Oct;6(10):722-34
pubmed: 26404030
Nat Rev Nephrol. 2016 May;12(5):281-90
pubmed: 27026348
Nature. 2017 Jun 29;546(7660):656-661
pubmed: 28636593
J Immunol. 2004 Feb 1;172(3):1531-9
pubmed: 14734731
Clin Transl Med. 2022 Jul;12(7):e958
pubmed: 35802825
Front Neurol. 2019 Apr 03;10:291
pubmed: 31001186
Front Neurol. 2018 Dec 21;9:1123
pubmed: 30622507
Glia. 2013 Mar;61(3):349-60
pubmed: 23108585
J Clin Neurol. 2019 Apr;15(2):135-142
pubmed: 30938106
J Immunol. 2016 Feb 15;196(4):1558-67
pubmed: 26746191
Nat Immunol. 2017 Aug;18(8):899-910
pubmed: 28604719
J Neuroimmunol. 2013 Dec 15;265(1-2):1-10
pubmed: 24210793
BMC Biochem. 2007 Nov 22;8 Suppl 1:S13
pubmed: 18047737
J Leukoc Biol. 2016 Sep;100(3):481-9
pubmed: 27354413
Rev Neurosci. 2019 Jul 26;30(5):455-462
pubmed: 30471223
Mov Disord. 2016 Feb;31(2):178-92
pubmed: 26813776
PLoS One. 2012;7(9):e45466
pubmed: 23029029
Nucl Med Commun. 2008 Mar;29(3):193-207
pubmed: 18349789
J Physiol. 2020 Dec;598(23):5427-5451
pubmed: 32893883
Mov Disord. 2018 Aug;33(8):1315-1324
pubmed: 29737566
Exp Mol Med. 2019 Sep 6;51(9):1-11
pubmed: 31492861
Int J Mol Sci. 2015 Mar 09;16(3):5400-19
pubmed: 25761244
J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881
pubmed: 30967444
Redox Biol. 2018 Apr;14:600-608
pubmed: 29154191
Prog Neurobiol. 2019 Jan;172:40-70
pubmed: 30009872
Front Cell Neurosci. 2019 Sep 18;13:421
pubmed: 31619964
Lancet Neurol. 2019 Jun;18(6):573-586
pubmed: 30981640
Ageing Res Rev. 2004 Jul;3(3):265-301
pubmed: 15231237
Int J Mol Sci. 2020 Dec 09;21(24):
pubmed: 33317145
Lancet Neurol. 2019 May;18(5):459-480
pubmed: 30879893
NPJ Parkinsons Dis. 2015;1:
pubmed: 27148593
J Biol Chem. 2003 Jun 20;278(25):22424-31
pubmed: 12690109
NPJ Parkinsons Dis. 2017 Jan 11;3:3
pubmed: 28649603
J Biol Chem. 2014 Oct 3;289(40):27776-93
pubmed: 25100717
Mol Neurodegener. 2022 Jan 10;17(1):7
pubmed: 35012605
JAMA Neurol. 2016 Nov 01;73(11):1316-1324
pubmed: 27668667

Auteurs

Mai M Abdelmoaty (MM)

Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Therapeutic Chemistry Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Giza, Egypt.
Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.

Jatin Machhi (J)

Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.

Pravin Yeapuri (P)

Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.

Farah Shahjin (F)

Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.

Vikas Kumar (V)

Mass Spectrometry and Proteomics Core, University of Nebraska Medical Center, Omaha, Nebraska, USA.

Katherine E Olson (KE)

Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.

R Lee Mosley (RL)

Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.

Howard E Gendelman (HE)

Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
ORCID: 0000-0002-7831-0370

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Monocyte biomarkers define sargramostim...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de croissance hématopoïétique › Facteurs de stimulation des colonies › Facteur de stimulation des colonies de granulocytes et de macrophages › Monocyte biomarkers define sargramostim...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Monocyte biomarkers define sargramostim...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Monocytes › Monocyte biomarkers define sargramostim...
questionsmedicales.fr › Maladies du système nerveux › Maladies neurodégénératives › Maladie de Parkinson › Monocyte biomarkers define sargramostim...
questionsmedicales.fr › Disciplines des sciences naturelles › Chimie › Biochimie › Protéomique › Monocyte biomarkers define sargramostim...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines recombinantes › Monocyte biomarkers define sargramostim...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Monocyte biomarkers define sargramostim...